Thierry Andre et al., 2004-06-03: Randomised trial of 2,246 resected stage II/III colon cancer patients comparing fluorouracil-leucovorin (FL) with FL plus oxaliplatin for six months. Three-year disease-free survival 78.2% versus 72.9%; grade 3 sensory neuropathy 12.4% during treatment.
The rate of disease-free survival at three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7) in the group given FL plus oxaliplatin and 72.9 percent (95 percent confidence interval, 70.2 to 75.7) in the FL group (P=0.002 by the stratified log-rank test).
Results (journal p. 2343)
Thierry Andre et al., 2004-06-03: Randomised trial of 2,246 resected stage II/III colon cancer patients comparing fluorouracil-leucovorin (FL) with FL plus oxaliplatin for six months. Three-year disease-free survival 78.2% versus 72.9%; grade 3 sensory neuropathy 12.4% during treatment. Funding: 'Supported by Sanofi-Synthelabo.' COI: Boni reports consulting fees from Sanofi-Synthelabo; Mounedji-Boudiaf and Tabah-Fisch are employed by Sanofi-Synthelabo; Topham reports equity ownership in Sanofi-Synthelabo and lecture fees; Hickish consulting and lecture fees. Manufacturer of oxaliplatin (Eloxatin): Sanofi-Synthelabo – i.e. the maker funded and co-authored the trial of its own drug. Comparator: FL alone (standard treatment). Primary endpoint was disease-free survival, not overall survival. Study type: randomized trial.
